... a dynamic, daily updated,
   fully relational, user-friendly,
   comprehensive resource in global 
   drug development in oncology
Subscriber Login
User ID:  

Follow oncology_drugs on Twitter


A free glossary of oncology-related terms and resource organizations.

About nm|OK

Why use a resource like nm|OK?
Unlike reports that are 'dead on arrival' nm|OK is a constantly updated comprehensive report on every aspect of oncology drug development.  click

Drugs profiled in nm|OK

nm|OK profiles over 4,310 drugs/in vivo imaging agents in development:

3,653 anticancer agents addressing over 100 cancer types and thousands of clinical indications. Of these, 1,695 are in active development; 821 have been or are currently being evaluated in clinical trials and 539 of these are targeted agents.

757 drugs for the management of complications of cancer and its treatment (pain, infection, mucositis, emesis, etc.)
nm|OK also profiles over 552 marketed drugs (anticancer agents=335, adjuncts=197) globally, providing trial results from monotherapy and combination therapy trials.

In vitro testing (IVT) products

nm|OK profiles over 200 companies and hundreds of products (screening tests, diagnostics, pharmacogenomics, prognostics, disease monitoring tests, theragnostics, etc.) in the in vitro testing area in oncology.

Enabling technologies/drug delivery

nm|OK describes hundreds of technology platforms used to discover, evaluate, optimize, and or deliver anticancer agents such as cytotoxics, synthetic nucleic acid sequences, small molecule drugs, monoclonal antibodies, fusion proteins, etc.

Targets in oncology

nm|OK describes over 1,000 molecular moieties that may be target candidates of anticancer strategies or used as in vitro testing markers. 

Shorthanded?  Need a cost-effective way to monitor developments in oncology. New Medicine provides numerous services:

Need an update on certain items in nm|OK?  click

Need to access certain records/saved searches on  a routine basis? click

Require more in-depth reports on certain developments in oncology? click

Would your oncology effort benefit from an in-house resource like nm|OK that allows you to combine nm|OK with secure proprietary data?  click


The headlines below refer to selected records among the hundreds updated in nm|OK within a 30-day period. A summary of the updated information, the complete records for each item on the list, and numerous other updated entries are available to subscribers upon logging in. Samples of records from each module are here.

Special Reports and Additional News


An Analytical Newsletter in the Global Oncology Field

From June 1995 to August 2008, New Medicine published Future Oncology, a comprehensive analytical newsletter tracking the evolution of global drug development in oncology. Despite of the incredible amount of effort in this area in the last 20 years, we currently face the same problems that were being tackled then, namely a lack of understanding as to the origins and mechanisms of malignancy. Despite the incredible global effort in this area and the remarkable scientific breakthroughs in biology and medicine, advanced cancer has remained an incurable disease. However, although cancer remains undefeated, treatment of this disease has created a huge global market comprised of drugs that, with few exceptions, provide marginal relief at a very high cost. Because the origins of this disease have remained obscure, there have been numerous approaches popularized at different times as to its treatment. Future Oncology has tracked these developments over time, from the rise of immunotherapy in the late 1990s to the subsequent discovery of oncogenes and tumor suppressors that shifted the emphasis from the labor intensive immunotherapy and gene transfer approaches to the relative simplicity of the production and delivery of monoclonal antibodies (MAb), oligonucleotides and small molecule drugs. Although some major advances have led to significant survival gains of patients with hematologic malignancies, they have not produced the same results in the treatment of metastatic solid tumors.

In the meantime, the competitive landscape underwent a major transformation. The archives follow the progress or demise of hundreds of commercial entities globally and hundreds of drugs, among some of the most successful to date as well some noted failures. The passage of time has produced many surprising winners and a few unexpected losers. Celgene, an unknown small company in 1995, has become a leading biotech juggernaut. Rituximab, a relatively low tech transformational therapy for the treatment of hematologic malignancies, developed by the small company Idec and approved in the USA in November 1997, may be considered the most successful anticancer agent to date both for significantly extending survival and for generating billions in sales for its developers and marketers. Since its first approval in 1995, Rituxan’s total global revenues exceeded $65 billion, including sales in the immunology sector beginning in FY 2013. Imatinib, launched in 2001, ushered the era of personalized medicine. Avastin, the first targeted treatment for solid tumors launched by Genentech in 2004, garnered over $60 billion in global revenues to date.

Currently, over 4,500 anticancer drugs are in development by over 1,000 companies globally. Molecularly targeted drugs have been dominating the oncology sector with over 800 targets being addressed by drugs in clinical development, but immune-oncology approaches are re-emerging with promising clinical results. Combination therapies are creating a highly complex drug development sector. Also, oncology drug approvals by regulators are at an unprecedented level and do are treatment costs.

The advent of targeted therapies has also created a robust commercial sector of companies developing in vitro tests (IVT) for every conceivable application. Currently, over 250 companies are developing pharmacogenomic assays, theragnostics, screening tests, companion diagnostics for patient selection, disease monitoring tests, etc. Over 1,000 molecular moieties have been linked to some aspect of malignancy and most of them are being evaluated as targets for the treatment of cancer, with many already approved and successfully commercialized. Genome sequencing is generating huge amounts of structural data that now needs to be interpreted as to its functional link to human disease. It is conceivable that ‘personalized medicine’ may come to literally mean a different therapeutic regimen for each patient with cancer!

Inhibition of the Vascular Endothelial Growth Factor (VEGF) Pathway for the Treatment of Cancer

The success of Avastin, an antiangiogenesis agent targeting the VEGF pathway, has prompted the development of numerous similarly acting agents. Avastin, with global revenues of $6,210.5 million in fiscal 2010, is the most commercially successful anticancer drug ever to reach the market. Future Oncology has published a review of VEGF inhibition in the treatment of cancer. (more...)

Future Oncology Archives

Subscribers to New Medicine's Oncology KnowledgeBASE (nm|OK), log in to access the version providing active links to nm|OK records.







New Drugs And Marketed Drugs

Company, Targets and In Vitro Tests



New Drugs
(click for detailed news feed)

Dalantercept ACE-041

Ofranergene obadenovec VB-111, GT-111

Tavokinogene telsaplasmid pIL-12, IT-pIL12-EP

Cytarabine:daunorubicin CPX-351


Marketed Drugs
(click for detailed news feed)







(click for detailed news feed)



Dragonfly Therapeutics

Apexian Pharmaceuticals

CTI BioPharma

Oncolytics Biotech



Targets in Oncology
(click for detailed news feed)

Semaphorin 3A (SEMA3A)
(Jun 14, 2017)

Splicing factor 3b, subunit 1 (SF3B1)

Alpha-2-glycoprotein 1, zinc-binding (AZGP1)



Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   

P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887